Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | REN | P00797 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13368327 | 0.89 | CA1 (0.44) | HCRTR1HCRTR2CYP3A4CA1CA2 | |
| SCHEMBL13341395 | 0.85 | HCRTR1 (0.42) | HCRTR1HCRTR2CYP3A4CA1CA2 | |
| SCHEMBL13368235 | 0.84 | HCRTR1 (0.35) | HCRTR1HCRTR2CYP3A4CA1CA2 | |
| Hydrochloric Acid SCHEMBL3493030 | 0.84 | HCRTR1 (0.42) | HCRTR1HCRTR2CYP3A4CA1CA2 | |
| SCHEMBL13368246 | 0.80 | REN (0.40) | HCRTR1HCRTR2CYP3A4CA1CA2 | |
| SCHEMBL3492134 | 0.77 | HCRTR1 (0.38) | HCRTR1HCRTR2CYP3A4RENALDH1A1 | |
| SCHEMBL3494532 | 0.75 | HCRTR1 (0.44) | HCRTR1HCRTR2CYP3A4CA1CA2 | |
| SCHEMBL8236184 | 0.73 | HCRTR1 (0.53) | HCRTR1HCRTR2CYP3A4CA1CA2 | |
| Hydrochloric Acid SCHEMBL3494081 | 0.73 | HCRTR1 (0.52) | HCRTR1HCRTR2CYP3A4CA1CA2 | |
| SCHEMBL13341376 | 0.72 | HCRTR1 (0.45) | HCRTR1HCRTR2CYP3A4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | HCRTR1 323/4885HCRTR2 255/4885CYP3A4 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.